Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study-Reference-Cited by-同舟云学术

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Published:2012-11-07 Issue:1 Volume:63 Page:72-79
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

van der Valk Mirthe Emilie,Mangen Marie-Josée J,Leenders Max,Dijkstra Gerard,van Bodegraven Ad A,Fidder Herma H,de Jong Dirk J,Pierik Marieke,van der Woude C Janneke,Romberg-Camps Mariëlle J L,Clemens Cees HM,Jansen Jeroen M,Mahmmod Nofel,van de Meeberg Paul C,van der Meulen-de Jong Andrea E,Ponsioen Cyriel Y,Bolwerk Clemens JM,Vermeijden J Reinoud,Siersema Peter D,van Oijen Martijn GH,Oldenburg Bas,

Publisher

BMJ

Subject

Gastroenterology

Reference33 articles.

1. Long-term evolution of disease behavior of Crohn's disease;Cosnes;Inflamm Bowel Dis,2002

2. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study;Bassi;Gut,2004

3. Burden of illness of Crohn's disease in Spain;Juan;Dig Liver Dis,2003

4. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation;Odes;Gastroenterol,2006

5. Inflammatory bowel diseases: health care and costs in Sweden in 1994;Blomqvist;Scand J Gastroenterol,1997

Cited by 427 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nursing Interventions Targeting Fatigue in Inflammatory Bowel Disease: A Systematic Review;Gastrointestinal Disorders;2024-08-05

2. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

3. Nutritional aspects in autoimmune diseases undergoing hematopoietic stem cell transplantation: overview and recommendations on behalf of the EBMT ADWP and Nurses Group;Frontiers in Nutrition;2024-05-09

4. Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-04-22

5. Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease;Alimentary Pharmacology & Therapeutics;2024-04-21